Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR, Bonavida B. Jazirehi AR, et al. Oncogene. 2005 Mar 24;24(13):2121-43. doi: 10.1038/sj.onc.1208349. Oncogene. 2005. PMID: 15789036 Review.
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.
Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS. Quatromoni JG, et al. Among authors: jazirehi ar. J Transl Med. 2012 Jun 19;10:127. doi: 10.1186/1479-5876-10-127. J Transl Med. 2012. PMID: 22713761 Free PMC article.
Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).
Torres-Collado AX, Knott J, Jazirehi AR. Torres-Collado AX, et al. Among authors: jazirehi ar. Cancers (Basel). 2018 May 24;10(6):157. doi: 10.3390/cancers10060157. Cancers (Basel). 2018. PMID: 29795041 Free PMC article. Review.
Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier.
Toress-Collado AX, Nazarian R, Jazirehi AR. Toress-Collado AX, et al. Among authors: jazirehi ar. Tumour Biol. 2017 Sep;39(9):1010428317721620. doi: 10.1177/1010428317721620. Tumour Biol. 2017. PMID: 28936920 Free article.
Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.
Dinh TN, Onea AS, Jazirehi AR. Dinh TN, et al. Among authors: jazirehi ar. Am J Clin Exp Immunol. 2017 May 15;6(3):27-42. eCollection 2017. Am J Clin Exp Immunol. 2017. PMID: 28804691 Free PMC article. Review.
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
Jazirehi AR, Lim A, Dinh T. Jazirehi AR, et al. Am J Cancer Res. 2016 Oct 1;6(10):2117-2128. eCollection 2016. Am J Cancer Res. 2016. PMID: 27822406 Free PMC article. Review.
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
Onea AS, Jazirehi AR. Onea AS, et al. Among authors: jazirehi ar. Am J Cancer Res. 2016 Jan 15;6(2):403-24. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186412 Free PMC article. Review.
Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS. Jazirehi AR, et al. Am J Clin Exp Immunol. 2014 Feb 27;3(1):43-56. eCollection 2014. Am J Clin Exp Immunol. 2014. PMID: 24660121 Free PMC article.
Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.
Jazirehi AR, Kurdistani SK, Economou JS. Jazirehi AR, et al. J Immunol. 2014 Apr 15;192(8):3981-9. doi: 10.4049/jimmunol.1302532. Epub 2014 Mar 17. J Immunol. 2014. PMID: 24639349 Free PMC article.
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
Jazirehi AR, Arle D. Jazirehi AR, et al. Am J Clin Exp Immunol. 2013 Feb 27;2(1):55-74. Print 2013. Am J Clin Exp Immunol. 2013. PMID: 23885325 Free PMC article.
49 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback